Drug Profile
Rovelizumab
Alternative Names: 23F2G; Hu23F2G; LeukArrestLatest Information Update: 17 May 2002
Price :
$50
*
At a glance
- Originator ICOS Corporation
- Class Anti-ischaemics; Monoclonal antibodies
- Mechanism of Action Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Cerebral vasospasm; CNS trauma; Multiple sclerosis; Myocardial infarction; Peripheral arterial occlusive disorders; Shock; Stroke; Vascular restenosis
Most Recent Events
- 17 May 2002 Discontinued - Preclinical for Cerebral vasospasm in USA (unspecified route)
- 17 May 2002 Discontinued - Preclinical for CNS trauma in USA (unspecified route)
- 17 May 2002 Discontinued - Preclinical for Peripheral arterial occlusive disorders in USA (unspecified route)